Education
About Us
Working with TipRanks
Follow Us
Corbus Pharmaceuticals (CRBP)
NASDAQ:CRBP
CRBP Stock Chart & Stats
$7.83
-$0.10(-0.79%)
At close: 4:00 PM EST
$7.83
-$0.10(-0.79%)
Day’s Range― - ―
52-Week Range$4.64 - $20.56
Previous CloseN/A
Volume39.58K
Average Volume (3M)503.64K
Market Cap
$137.44M
Enterprise Value$69.83M
Total Cash (Recent Filing)$26.98M
Total Debt (Recent Filing)$2.05M
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Mar 17, 2026EPS Estimate
-1.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.90
Shares Outstanding17,553,038
10 Day Avg. Volume744,820
30 Day Avg. Volume503,638
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.90
Price to Sales (P/S)0.00
P/FCF Ratio-3.08
Enterprise Value/Market Cap0.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.40
Enterprise Value/Ebitda-1.01
Forecast
1Y Price Target
$47.60Price Target Upside507.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Development PathwayStrong response signals for CRB-701 in head and neck cancer support planned FDA discussions and a registrational monotherapy trial targeted to begin by mid-2026, offering a clear path toward potential approval.
Financial RunwayExtended cash runway into 2028 reduces near-term financing pressure and supports continued development of both oncology and metabolic programs.
Pipeline DiversificationDevelopment of CRB-913 expands exposure into the large obesity market with a peripherally restricted CB1 approach that could provide a differentiated alternative to existing therapies.
Bears Say
Disclosure And Information RiskManagement's indication that full CRB-913 results may not be published increases information risk and could hinder investor confidence when evaluating long-term program prospects.
Efficacy UncertaintyWeight-loss potential for CRB-913 is uncertain because early studies enrolled predominantly healthy volunteers and may not predict outcomes in obesity patients or overcome early weight-loss plateaus.
Neuropsychiatric Risk OverhangHistorical neuropsychiatric concerns for CB1-targeting drugs, combined with a small number of anxiety reports in obese cohorts, could continue to weigh on investor sentiment and regulatory scrutiny.
Corbus Pharmaceuticals News
CRBP FAQ
What was Corbus Pharmaceuticals’s price range in the past 12 months?
Corbus Pharmaceuticals lowest stock price was $4.64 and its highest was $20.56 in the past 12 months.
What is Corbus Pharmaceuticals’s market cap?
Corbus Pharmaceuticals’s market cap is $137.44M.
When is Corbus Pharmaceuticals’s upcoming earnings report date?
Corbus Pharmaceuticals’s upcoming earnings report date is Mar 17, 2026 which is in 31 days.
How were Corbus Pharmaceuticals’s earnings last quarter?
Corbus Pharmaceuticals released its earnings results on Nov 12, 2025. The company reported -$1.9 earnings per share for the quarter, missing the consensus estimate of -$1.657 by -$0.243.
Is Corbus Pharmaceuticals overvalued?
According to Wall Street analysts Corbus Pharmaceuticals’s price is currently Undervalued.
Does Corbus Pharmaceuticals pay dividends?
Corbus Pharmaceuticals does not currently pay dividends.
What is Corbus Pharmaceuticals’s EPS estimate?
Corbus Pharmaceuticals’s EPS estimate is -1.54.
How many shares outstanding does Corbus Pharmaceuticals have?
Corbus Pharmaceuticals has 17,553,038 shares outstanding.
What happened to Corbus Pharmaceuticals’s price movement after its last earnings report?
Corbus Pharmaceuticals reported an EPS of -$1.9 in its last earnings report, missing expectations of -$1.657. Following the earnings report the stock price went up 7.39%.
Which hedge fund is a major shareholder of Corbus Pharmaceuticals?
Currently, no hedge funds are holding shares in CRBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Corbus Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$47.60 (507.92% Upside)
$47.60 (507.92% Upside)
Hedge Fund Trend
Decreased
By 15.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $389.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 10.7%
Last 30 Days ▼ 10.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-43.19%
12-Months-Change
Fundamentals
Return on Equity
-55.65%
Trailing 12-Months
Asset Growth
-17.70%
Trailing 12-Months
Company Description
Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
CRBP Stock 12 Month Forecast
Average Price Target
$47.60
▲(507.92% Upside)
Technical Analysis
Ownership Overview
15.84% Insiders
3.98% Mutual Funds
1.10% Other Institutional Investors
73.55% Public Companies and
Individual Investors